Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Oasis Medical, Inc.
WARNING LETTER
•Oasis Medical, Inc.•January 27, 2025

Oasis Medical, Inc. – FDA Warning Letter, Jan 27, 2025

Record Details

Oasis Medical, Inc., located at 514 S. Vermont Avenue, Glendora, CA, was inspected by the FDA from January 15 to 27, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, as outlined in 21 CFR parts 210 and 211. These violations render the drug products adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

Key issues identified include the failure to establish adequate written procedures for production and process control, leading to inconsistencies in drug identity, strength, quality, and purity. The firm relied excessively on visual inspections without addressing the root causes of visible particulates and critical defects. Additionally, Oasis Medical did not validate in-process hold times or commit to addressing potentially contaminated products already distributed.

The firm also failed to thoroughly investigate discrepancies or failures in batch specifications, particularly concerning sterility and bioburden test results. For instance, a sterility failure in VISCO SHIELD Topical Drops was inadequately investigated, with conflicting conclusions between the firm and its contract laboratory. Similarly, pre-sterilization bioburden results exceeding specifications were not properly addressed, lacking identification of microbes or potential root causes.

Furthermore, Oasis Medical did not establish laboratory controls with scientifically sound specifications and failed to implement an adequate stability testing program to determine appropriate storage conditions and expiration dates.

The FDA requires Oasis Medical to provide a comprehensive response addressing these violations, including corrective actions and timelines for implementation. The firm must ensure compliance with CGMP regulations to maintain product quality and safety.

Company
Oasis Medical, Inc.
Inspection date
January 27, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · b78ad1b2-dc01-4b20-b879-a30fe1945c36

Violation Codes10
21 CFR 21021 CFR 21121 U.S.C. 351(a)(2)(B)21 CFR 211.100(a)21 CFR 211.19221 CFR 211.160(b)21 CFR 211.166(a)21 CFR 211.22(a)21 CFR 211.22(d)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Other documents for Oasis Medical, Inc.
  • 483 - 2025-01-27January 27, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Oasis Medical, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.